Role of IL-6 inhibitor in treatment of COVID-19-related cytokine release syndrome.
Role of IL-6 inhibitor in treatment of COVID-19-related cytokine release syndrome.
复制标题
DOI:
10.7150/ijms.53564
复制
发表时间:
2021
影响因子:
3.6
通讯作者:
Wang Y
中科院分区:
文献类型:
--
作者:
Du P;Geng J;Wang F;Chen X;Huang Z;Wang Y
Cytokine release syndrome (CRS) may be the key factor in the pathology of severe coronavirus disease 2019 (COVID-19). As a major driver in triggering CRS in patients with COVID-19, interleukin-6 (IL-6) appears to be a promising target for therapeutics. The results of inhibiting both trans- and classical- signaling with marketed IL-6 inhibitors (tocilizumab, siltuximab and sarilumab) in severe COVID-19 patients are effective based on several small studies and case reports thus far. In this review, we described the evidence of the IL-6 response in patients with COVID-19, clarified the pathogenesis of the role of IL-6-mediated CRS in severe COVID-19, and highlighted the rationale for the use of anti-IL-6 agents and key information regarding the potential features of these IL-6 inhibitors in COVID-19 patients.
登录
查看更多内容
DOI:
10.1038/nrclinonc.2017.148
发表时间:
2018-01
期刊:
Nature reviews. Clinical oncology
影响因子:
--
作者:
Neelapu SS;Tummala S;Kebriaei P;Wierda W;Gutierrez C;Locke FL;Komanduri KV;Lin Y;Jain N;Daver N;Westin J;Gulbis AM;Loghin ME;de Groot JF;Adkins S;Davis SE;Rezvani K;Hwu P;Shpall EJ
通讯作者:
Shpall EJ
DOI:
10.3760/cma.j.issn.1001-0939.2020.0005
发表时间:
2020-02-06
期刊:
Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
影响因子:
--
作者:
Chen, L;Liu, H G;Wei, S
通讯作者:
Wei, S
影响因子:
11.5
作者:
Deisseroth, Albert;Ko, Chia-Wen;Pazdur, Richard
通讯作者:
Pazdur, Richard
影响因子:
8.8
作者:
Barkhausen, Tanja;Tschernig, Thomas;Waetzig, Georg H.
通讯作者:
Waetzig, Georg H.
影响因子:
64.8
作者:
KOPF, M;BAUMANN, H;KOHLER, G
通讯作者:
KOHLER, G